Cargando…
Synthesis of a Bone-Targeted Bortezomib with In Vivo Anti-Myeloma Effects in Mice
Multiple myeloma (MM) is the most common cancer affecting the bone and bone marrow and remains incurable for most patients; novel therapies are therefore needed. Bortezomib (Btz) is an FDA-approved drug for the treatment of patients with MM. However, its severe side effects require a dose reduction...
| Autores principales: | , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
MDPI
2018
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6161102/ https://www.ncbi.nlm.nih.gov/pubmed/30201882 http://dx.doi.org/10.3390/pharmaceutics10030154 |